Get Premium to unlock powerful stock data
89bio Inc logo

89bio Inc

$ 2.96 +0.09 (+3.14%) 10:08 PM EST
P/E:
At Loss
P/B:
0.56
Market Cap:
$ 60.24M
Enterprise V:
$ -48.20M
Volume:
222.37K
Avg Vol (2M):
218.32K
Volume:
222.37K
Market Cap $:
60.24M
PE Ratio:
At Loss
Avg Vol (2-Month):
218.32K
Enterprise Value $:
-48.20M
PB Ratio:
0.56
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

89bio Inc
NAICS : 325412 SIC : 2834
142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104
Description
89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Name Current Vs Industry Vs History
Cash-To-Debt 6.48
Equity-to-Asset 0.76
Debt-to-Equity 0.19
Debt-to-EBITDA -0.2
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -10.5
3-Year EPS without NRI Growth Rate 16.2
3-Year FCF Growth Rate -11.9

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 77.38
9-Day RSI 64.99
14-Day RSI 55.67
6-1 Month Momentum % -82.37
12-1 Month Momentum % -87.3

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.36
Quick Ratio 7.36
Cash Ratio 6.85

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -64.3
Name Current Vs Industry Vs History
ROE % -68.33
ROA % -59.59
ROIC % -2168.49
ROC (Joel Greenblatt) % -18012.23
ROCE % -64.77

Financials (Next Earnings Date:2022-08-12 Est.)

ETNB's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ETNB

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -5
Beta 0
Volatility % 69.46
14-Day RSI 55.67
14-Day ATR ($) 0.292601
20-Day SMA ($) 2.481
12-1 Month Momentum % -87.3
52-Week Range ($) 2 - 23.07
Shares Outstanding (Mil) 20.35

Piotroski F-Score Details

Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

89bio Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More